3 Stocks Moving The Health Services Industry Upward - TheStreet

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 127.73 points (-0.8%) at 16,384 as of Tuesday, May 20, 2014, 3:55 PM ET. The NYSE advances/declines ratio sits at 774 issues advancing vs. 2,216 declining with 147 unchanged.

The Health Services industry as a whole closed the day down 0.8% versus the S&P 500, which was down 0.5%. Top gainers within the Health Services industry included

American Shared Hospital Services

(

AMS

), up 9.6%,

Pro-Dex

(

PDEX

), up 3.8%,

Misonix

(

MSON

), up 6.3%,

Vision-Sciences Inc (DE

(

VSCI

), up 2.2% and

Biocept

(

BIOC

), up 3.8%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Biocept

(

BIOC

) is one of the companies that pushed the Health Services industry higher today. Biocept was up $0.17 (3.8%) to $4.68 on light volume. Throughout the day, 6,250 shares of Biocept exchanged hands as compared to its average daily volume of 21,600 shares. The stock ranged in a price between $4.31-$4.68 after having opened the day at $4.31 as compared to the previous trading day's close of $4.51.

Biocept has a market cap of $19.6 million and is part of the health care sector. Shares are unchanged year-to-date as of the close of trading on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on BIOC go as follows:

You can view the full analysis from the report here:

Biocept Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close,

Vision-Sciences Inc (DE

(

VSCI

) was up $0.02 (2.2%) to $1.07 on light volume. Throughout the day, 14,340 shares of Vision-Sciences Inc (DE exchanged hands as compared to its average daily volume of 91,500 shares. The stock ranged in a price between $1.06-$1.09 after having opened the day at $1.06 as compared to the previous trading day's close of $1.05.

Vision-Sciences, Inc., together with its subsidiaries, engages in the design, development, manufacture, and marketing of endoscopy products. The company operates in two segments, Medical and Industrial. Vision-Sciences Inc (DE has a market cap of $49.0 million and is part of the health care sector. Shares are up 3.0% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Vision-Sciences Inc (DE a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Vision-Sciences Inc (DE as a

sell

. The company's weaknesses can be seen in multiple areas, such as its poor profit margins, generally disappointing historical performance in the stock itself and unimpressive growth in net income.

Highlights from TheStreet Ratings analysis on VSCI go as follows:

  • The gross profit margin for VISION-SCIENCES INC is currently lower than what is desirable, coming in at 31.02%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -48.08% is significantly below that of the industry average.
  • In its most recent trading session, VSCI has closed at a price level that was not very different from its closing price of one year earlier. This is probably due to its weak earnings growth as well as other mixed factors. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • The change in net income from the same quarter one year ago has exceeded that of the Health Care Equipment & Supplies industry average, but is less than that of the S&P 500. The net income has decreased by 15.8% when compared to the same quarter one year ago, dropping from -$2.07 million to -$2.40 million.
  • VISION-SCIENCES INC's earnings per share declined by 25.0% in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, VISION-SCIENCES INC continued to lose money by earning -$0.16 versus -$0.22 in the prior year.
  • Net operating cash flow has increased to -$1.37 million or 44.79% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 5.14%.

You can view the full analysis from the report here:

Vision-Sciences Inc (DE Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Misonix

(

MSON

) was another company that pushed the Health Services industry higher today. Misonix was up $0.37 (6.3%) to $6.23 on light volume. Throughout the day, 5,340 shares of Misonix exchanged hands as compared to its average daily volume of 9,700 shares. The stock ranged in a price between $5.90-$6.23 after having opened the day at $5.90 as compared to the previous trading day's close of $5.86.

Misonix, Inc. designs, develops, manufactures, and markets minimally invasive ultrasonic surgical device products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical applications. Misonix has a market cap of $42.2 million and is part of the health care sector. Shares are up 4.1% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Misonix a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Misonix as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and a generally disappointing performance in the stock itself.

Highlights from TheStreet Ratings analysis on MSON go as follows:

  • The revenue growth came in higher than the industry average of 2.9%. Since the same quarter one year prior, revenues rose by 23.4%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • MSON has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 3.56, which clearly demonstrates the ability to cover short-term cash needs.
  • MISONIX INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, MISONIX INC reported poor results of -$0.40 versus -$0.09 in the prior year. This year, the market expects an improvement in earnings (-$0.01 versus -$0.40).
  • In its most recent trading session, MSON has closed at a price level that was not very different from its closing price of one year earlier. This is probably due to its weak earnings growth as well as other mixed factors. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, MISONIX INC's return on equity significantly trails that of both the industry average and the S&P 500.

You can view the full analysis from the report here:

Misonix Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.